转移性激素敏感性前列腺癌患者的CDK12突变频率及临床意义#br##br#

目的研究中国人群中转移性激素敏感性前列腺癌（mHSPC）患者的CDK12突变频率,明确其对mHSPC的预后意义。方法选择南京大学医学院附属鼓楼医院泌尿外科2019年1月至2020年11月91例mHSPC患者,用第二代测序NGS技术检测其CDK12的突变频率,收集患者的临床信息,通过患者进展至mCRPC阶段的时间分析CDK12突变的预后作用。结果91例患者中共有11例患者检测出CDK12有害突变,突变频率为1209%。CDK12突变状态与mHSPC患者是否在12个月内进展至mCRPC阶段存在相关性（χ2=6278,P=0012）。Logistic回归分析显示CDK12突变显著增加了mHSPC患者是否在12个月内进展至mCRPC阶段的风险（OR=586,95% CI：146～2349,P=0013）。同时,ISUP分组也是一项独立危险因素（OR=292,95%CI：123～692,P=0015）。结论CDK12在中国人群中的突变频率远高于外国人群。CDK12是一种重要的不良预后指标,可以作为mHSPC患者判断预后的有效生物标志物。

Frequency and clinical significance of CDK12 mutation in Metastatic Hormone-sensitive Prostate Cancer from Chinese patients

ObjectiveTo investigate the frequency and prognostic significance of CDK12 mutation in Metastatic Hormone sensitive Prostate(mHSPC)from Chinese patients. MethodsThe frequency of CDK12 mutation of 91 patients with mHSPC were detected by Next Generation Sequencing(NGS). The clinical information of patients was collected. The prognostic significance of CDK12 mutation was analyzed by time to castration resistance. ResultsWe detected CDK12 mutation in 11 of 91(1209%)patients. There was a significant difference between CDK12 mutation and time to castration resistance(χ2=6278,P=0012). Logistic regression analysis showed that CDK12 mutation significantly increased the risk of mHSPC patients progressing to mCRPC stage within 12 months(OR=586, 95% CI：146 2349, P=0013). Also, the ISUP subgroup was an independent risk factor(OR=292, 95% CI：123 692, P=0015). ConclusionsThe frequency of CDK12 mutation in Chinese population is much higher than that in Caucasian. CDK12 is an important indicator of poor prognostic, which can be used as an effective biomarker to predict the prognosis of patients with mHSPC.